Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Enrolling by invitation

Conditions studied: Hematologic Malignancies, Solid Tumors

In brief

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Key facts

Study ID

NCT06925685

Run by

Allogene Therapeutics

People needed

50

Starts

2025-01-31

Expected to finish

2039-01-01

Last updated by the study team

2025-04-13

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received an allogenic CAR T-cell product infusion to treat an oncologic condition in a previous Allogene or Servier sponsored clinical study

You may not qualify if…

• Less than 12 months of follow up after the last allogeneic CAR T-cell product, unless approved by the Allogene Medical Monitor

Where it is running

• Circuit Clinical — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.